Search

Your search keyword '"Masahiko Kaito"' showing total 53 results

Search Constraints

Start Over You searched for: Author "Masahiko Kaito" Remove constraint Author: "Masahiko Kaito" Topic business.industry Remove constraint Topic: business.industry
53 results on '"Masahiko Kaito"'

Search Results

1. Elevation of branched-chain amino acid levels in diabetes and NAFL and changes with antidiabetic drug treatment

2. Multi-center clinical studies for strategies to improve patients' accessibility to peginterferon therapy: Consideration based on both prospective study and retrospective study

3. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion

4. BCAA-enriched snack improves nutritional state of cirrhosis

5. Hepcidin Expression in the Liver: Relatively Low Level in Patients with Chronic Hepatitis C

6. Decreased protein C activation in patients with fulminant hepatic failure

7. Upregulation of transferrin receptor 2 and ferroportin 1 mRNA in the liver of patients with chronic hepatitis C

8. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan

9. Single photon emission computed tomography and statistical parametric mapping analysis in cirrhotic patients with and without minimal hepatic encephalopathy

10. Improvement of regional cerebral blood flow after treatment with branched-chain amino acid solutions in patients with cirrhosis

11. Role of UGT1A1 mutation in fasting hyperbilirubinemia

12. Evaluating response to nutritional therapy using the branched-chain amino acid/tyrosine ratio in patients with chronic liver disease

13. Severe alcoholic hepatitis resulting in liver transplantation: The first case in Japan

14. Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy

15. Appropriate Interferon-alpha Therapy for Chronic Hepatitis C: An Assessment by Quantitative Changes in Serum Hepatitis C Virus-RNA

16. Current state of Wilson disease patients in central Japan

17. Consecutive follow up of liver volume change measured by computed tomography in a survived case of idiopathic acute fatty liver of pregnancy

18. Ineffective interferon treatment of chronic hepatitis C-associated porphyria cutanea tarda, but with a transient decrease in HCV RNA levels

19. Patients achieving clearance of HCV with interferon therapy recover from decreased retinol-binding protein 4 levels

20. Impaired regulation of serum hepcidin during phlebotomy in patients with chronic hepatitis C

21. Value of the apparent diffusion coefficient for quantification of low-grade hepatic encephalopathy

22. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C

23. Molecular mechanism of iron metabolism and overload in chronic hepatitis C

24. Influence of phlebotomy on iron-related gene expression levels in the livers of patients with chronic hepatitis C

25. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane

26. Elevation of 8-isoprostane in patients with hepatitis C virus infection undergoing hemodialysis

27. Effects of bezafibrate in patients with chronic hepatitis C virus infection: combination with interferon and ribavirin

28. Iron reduction therapy by phlebotomy reduces lipid peroxidation and oxidative stress in patients with chronic hepatitis C

29. Role of transferrin receptor 2 in hepatic accumulation of iron in patients with chronic hepatitis C

30. Iron content and consumption of health foods by patients with chronic hepatitis C

31. Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C

32. Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis

33. Polymorphism of UDP-glucuronosyltransferase 1A7 gene: a possible new risk factor for lung cancer

34. Core protein of hepatitis C virus induces cardiomyopathy

35. Increased hepatic and renal expressions of multidrug resistance-associated protein 3 in Eisai hyperbilirubinuria rats

36. Nonimmune complexed HCV RNA titer in serum as a predictor of interferon response in patients with chronic hepatitis C

37. Cerebral blood flow in basal ganglia is correlated with clinical signs of hepatic encephalopathy in patients with liver cirrhosis

38. Decrease of regional cerebral blood flow in liver cirrhosis

39. High prevalence of transfusion-transmitted virus among patients with non-B, non-C hepatocellular carcinoma

40. Conjugated bilirubin decreases the biliary excretion of phospholipids

41. Case report: Alanine aminotransferase deficiency detected in a patient with chronic hepatitis C

42. Hepatotoxicity associated with Lyophyllum decastes Sing. (Hatakeshimeji)

43. Accumulation of 8-n itroguanine in the liver of chronic hepatitis C patients without sustained virological response after completion of interferon therapy

44. Use of lactoferrin for chronic hepatitis C

45. Dietary fiber decreases ammonia levels in patients with cirrhosis

46. 'Green Juice'–Associated Granulomatous Hepatitis

47. Lactoferrin inhibits hepatitis C virus viremia in chronic hepatitis C patients with high viral loads and HCV genotype 1b

48. 257 SELDI PROTEINCHIP SERUM ANALYSIS TO PREDICT VIROLOGICAL RESPONSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGYLATED INTERFERON PLUS RIBAVIRIN

49. Mutation of Ugt1a1 Gene in A Case of Crigler-Najjar Syndrome Type Ii

50. Reduction of Serum HCV RNA Titer by Bezafibrate Therapy in Patients with Chronic Hepatitis C

Catalog

Books, media, physical & digital resources